T1	Disease 104 112	melanoma
T2	NumberOfSamples 34741 34744	472
T3	SupplementaryFile 34849 34870	Supplementary Table 1
T4	FractionationMethod 44531 44576	UltiMate 3000 RSLCnano-capillary UHPLC system
T5	Instrument 44670 44685	Q-Exactive-Plus
T6	Time 44771 44774	2 h
T7	FlowRateChromatogram 44842 44857	0.15 microl/min
T8	FragmentationMethod 44945 44983	higher-energy collisional dissociation
T9	FragmentationMethod 44985 44988	HCD
*	Equiv T8 T9
T10	CollisionEnergy 45290 45293	25%
T11	TechnologyType 45448 45472	MaxQuant version 1.5.3.8
T12	AcquisitionMethod 44885 44899	data-dependent
T13	AcquisitionMethod 44901 44915	top 10" method
T14	Modification 45638 45660	N-terminal acetylation
A1	Modification T14 variable
T15	Modification 45680 45700	methionine oxidation
A2	Modification T15 variable
T16	AcquisitionMethod 45831 45856	match between runs option
T17	OutOfScope 46089 46098	PXD015957
T18	FractionationMethod 44293 44424	capillary reversed-phase chromatography on 075 x 300 mm laser-pulled capillaries, self-packed with C18 reversed-phase 3.5 mum beads
T19	CleavageAgent 43365 43374	Protein-A
T20	FractionationFraction 44092 44107	eluted peptides
T21	Genotype 383 416	overexpression of PSMB8 and PSMB9
T22	SampleTreatment 43089 43117	protease inhibitors cocktail
T23	NumberOfTechnicalReplicates 42782 42787	three
T24	Temperature 43207 43217	4 degreesC
T25	Time 43222 43225	1 h
T26	CellLine 37571 37574	12T
T27	CellLine 37579 37583	108T
T28	CellLine 37824 37828	A375
T29	SupplementaryFile 38148 38170	Supplementary Table 16
T30	SupplementaryFile 38041 38068	Supplementary Tables 14, 15
T31	CellType 38188 38195	B-cells
T32	CellLine 38260 38264	HB95
T33	CellType 38244 38253	Hybridoma
T34	Organism 38802 38807	Human
T35	Genotype 38808 38818	PSMB8 cDNA
T36	Genotype 38881 38891	PSMB9 cDNA
